CALCIMEDICA ANNOUNCES THAT FDA HAS STRONGLY RECOMMENDED MOVING TO A BLINDED PLACEBO-CONTROLLED TRIAL WITH AUXORA™ IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA

/in

LA JOLLA, Calif., May 21, 2020 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of acute and severe inflammatory diseases, today announced that it has received guidance from the U.S. Food and Drug Administration (FDA) regarding the Company’s ongoing study of Auxora™ (formerly called […]

Read more

Adherium progresses U.S. sales agreement with respiratory device U.S. market leader Monaghan Medical Corporation, a member of the Trudell Medical Group of Companies

/in

Link to Full Article Melbourne, Australia – 29 April 2020: Adherium Limited (ASX:ADR), a leader in digital inhaled device adherence, remote monitoring and data management solutions, has signed a heads of terms sales agreement with Monaghan Medical Corporation, a US subsidiary of Trudell Medical Limited, the parent company of a multinational group of leading companies […]

Read more

Adherium announces appointment of Mr. Mike Motion as Chief Executive Officer and Ms. Anne Bell as Chief Financial Officer

/in

Link to Full Article Melbourne, Australia – 24 April 2020: Adherium (ASX:ADR) today announced the promotion of Mr Mike Motion from Chief Operating Officer to the role of Chief Executive Officer, replacing Mr Jeremy Curnock Cook who has held the position on an interim basis. Mike will also join the Board as an Executive Director, […]

Read more

Adherium and Planet Innovation partner to develop inhaled medication adherence devices and enhanced digital software platform

/in

Link to Full Article Melbourne, Australia – 21 April 2020: Adherium (ASX:ADR), a leader in digital inhaled device adherence, remote monitoring and data management solutions, today announced a strategic device hardware and software development partnership with Planet Innovation (PI). This development will enhance Adherium’s leading device coverage position in both asthma and COPD with sensors […]

Read more

Adherium announces first US disease management collaboration in COPD with HGE Health

/in

Link to Full Article Melbourne, Australia – 16 April 2020: Adherium Limited (ASX:ADR), a leader in digital inhaled device adherence, remote monitoring and data management solutions, has agreed a US disease management collaboration with Pennsylvania-based HGE Health. Both parties will rapidly evaluate and integrate Adherium’s sensor and software technology into HGE Health’s established telemedicine platform […]

Read more

Appointment of Mr. James Ward-Lilley as a Director and Chairman

/in

Link to Full Article 14 April 2020 – Adherium (ASX:ADR) announces that James Ward-Lilley who has been consulting to Adherium over recent months has joined the Adherium Board of Directors, and following the untimely death of Thomas Lynch, James has also been appointed Chairman of the Board. Mr. Ward-Lilley commented “I am pleased to be […]

Read more

Adherium announces death of Chairman, Thomas Lynch

/in

Link to Full Article 8 April 2020 – Adherium (ASX:ADR) announces with considerable sadness the unfortunate and untimely death of its Chairman, Thomas Lynch. Tom had been Chairman at Adherium since joining the Board in September 2016, and the Directors and staff of Adherium send their deepest condolences to Tom’s family at this very sad […]

Read more

Half Yearly Report and Accounts

/in

Link to Full Article Adherium Limited ABN 24 605 352 510 Appendix 4D   Interim Consolidated Financial Report for the six months ended 31 December 2019   Adherium Limited (“Adherium”, the “Company” or the “Group”) presents this financial report, including the interim financial statements, for the six months ended 31 December   Results for announcement […]

Read more

Adherium Raises $5.4 million to Complete Rights Issue and Shortfall Placement

/in

  Link to Full Article 11 February 2020 – Adherium Limited (ASX:ADR), a global leader in digital health technologies that address sub-optimal medication use in chronic disease, has successfully reached its target of $5.4 million raised through its Rights Issue allocating 17,517,309 shares in entitlement subscriptions and 162,206,104 shortfall shares to wholesale and exempt […]

Read more

Saluda Medical Highlights Multiple Presentations Featuring Evoke® ECAP-Controlled, Closed-Loop SCS System at NANS Annual Meeting

/in

Link to Full Article ARTARMON, NSW, Australia, January 21, 2020 – Saluda Medical Pty Limited (“Saluda Medical”) today announced that data from multiple studies evaluating the company’s Evoke® ECAP-Controlled, Closed-Loop Spinal Cord Stimulation (SCS) System for the treatment of chronic pain will be featured in multiple presentations – including eight oral presentations and award of Best Clinical Abstract – during […]

Read more